Cadonilimab plus chemo for recurrent pleural mesothelioma
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new drug, cadonilimab, combined with standard chemotherapy for people with pleural mesothelioma that has come back after platinum-based treatment. The goal is to see if this combination can shrink tumors or slow the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have pleural mesothelioma that has spread or cannot be removed by surgery.
- You have tried platinum-based chemotherapy (with or without bevacizumab) and it no longer works.
- You have not had more than two prior treatment regimens for your mesothelioma.
- You are in generally good health, able to care for yourself (ECOG 0 or 1).
- You have measurable tumors that can be tracked by CT or MRI scans.
- Your blood counts and liver/kidney function are adequate.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding cadonilimab (an immune treatment) and bevacizumab (a medicine that targets blood supply to tumors) to standard chemotherapy can control pleural malignant mesothelioma that cannot be removed with surgery. It’s meant for people who have not yet started medicine for advanced disease and who meet health and blood test requirements.
This trial studies how well pembrolizumab (an immune therapy) works when added to chemotherapy before image-guided surgery for malignant pleural mesothelioma. It aims to shrink or control the cancer and improve surgical results by combining treatments.
This trial is testing a new immunotherapy drug (ivonescimab) combined with chemotherapy for people with mesothelioma that has already been treated. It aims to see if this combination can shrink tumors or slow the disease.
This trial tests adding a drug called fianlimab to another drug (cemiplimab) plus chemotherapy for people with a type of lung cancer called pleural mesothelioma. It aims to see if the combination is more effective than cemiplimab plus chemo alone.
This trial tests a new immunotherapy drug called cadonilimab combined with chemotherapy as a first treatment for people with advanced non-squamous non-small cell lung cancer that does not have the PD-L1 protein. The goal is to see if this combination works better than standard treatments.
This Phase 2 study tests whether adding three medicines—sintilimab, anlotinib, and standard platinum chemo—can control malignant pleural mesothelioma that cannot be removed by surgery. It may help shrink tumors and slow disease progression, but you must meet specific health and prior-treatment requirements.
Hear when a new Pleural Mesothelioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.